Last reviewed · How we verify
Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
At a glance
| Generic name | Vortioxetine Hemihydrobromide Orally Disintegrating Tablets |
|---|---|
| Also known as | SF001 ODT |
| Sponsor | Seasons Biotechnology (Taizhou) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Food Effect Bioavailability Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets (PHASE1)
- Single Dose Study to Evaluate Dose-proportionality of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets (PHASE1)
- Single Dose Oral Bioequivalence Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: